Organon & annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Organon & Stock-Based Compensation Growth & History (OGN)
Organon &'s stock-based compensation was $77.0M for fiscal 2025.
View full Organon & company overviewOrganon & annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $77.0M | −$28.0M | −26.67% |
| 2024 | 2024-12-31 | $105.0M | $4.0M | +3.96% |
| 2023 | 2023-12-31 | $101.0M | $26.0M | +34.67% |
| 2022 | 2022-12-31 | $75.0M | $16.0M | +27.12% |
| 2021 | 2021-12-31 | $59.0M | $19.0M | +47.50% |
| 2020 | 2020-12-31 | $40.0M | −$1.0M | −2.44% |
| 2019 | 2019-12-31 | $41.0M | — | — |
Organon & quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $25.0M | $3.0M | +13.64% |
| Q1 2026 | 2026-03-31 | $19.0M | −$5.0M | −20.83% |
| Q4 2025 | 2025-12-31 | $7.0M | −$19.0M | −73.08% |
| Q3 2025 | 2025-09-30 | $24.0M | −$1.0M | −4.00% |
| Q2 2025 | 2025-06-30 | $22.0M | −$6.0M | −21.43% |
| Q1 2025 | 2025-03-31 | $24.0M | −$2.0M | −7.69% |
| Q4 2024 | 2024-12-31 | $26.0M | −$1.0M | −3.70% |
| Q3 2024 | 2024-09-30 | $25.0M | −$2.0M | −7.41% |
| Q2 2024 | 2024-06-30 | $28.0M | $3.0M | +12.00% |
| Q1 2024 | 2024-03-31 | $26.0M | $4.0M | +18.18% |
| Q4 2023 | 2023-12-31 | $27.0M | $4.0M | +17.39% |
| Q3 2023 | 2023-09-30 | $27.0M | $9.0M | +50.00% |
| Q2 2023 | 2023-06-30 | $25.0M | $6.0M | +31.58% |
| Q1 2023 | 2023-03-31 | $22.0M | $7.0M | +46.67% |
| Q4 2022 | 2022-12-31 | $23.0M | — | — |
| Q3 2022 | 2022-09-30 | $18.0M | $3.0M | +20.00% |
| Q2 2022 | 2022-06-30 | $19.0M | $1.0M | +5.56% |
| Q1 2022 | 2022-03-31 | $15.0M | $4.0M | +36.36% |
| Q3 2021 · Sep 30 | 2021-09-30 | $15.0M | $4.0M | +36.36% |
| Q2 2021 | 2021-06-30 | $18.0M | $7.0M | +63.64% |
| Q1 2021 | 2021-03-31 | $11.0M | $1.0M | +10.00% |
| Q4 2020 | 2020-12-31 | $8.0M | — | — |
| Q3 2020 | 2020-09-30 | $11.0M | — | — |
| Q2 2020 | 2020-06-30 | $11.0M | — | — |
| Q1 2020 | 2020-03-31 | $10.0M | — | — |
Organon & stock-based compensation trends
Over the last five fiscal years, Organon &'s stock-based compensation increased from $40.0M to $77.0M, a change of $37.0M. The latest reported quarter, Q2 2026, shows $25.0M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Organon & source filings ↗